On this page
The words on the vial are still the seller's. HHS filed a draft the same day that treats foreign research-use-only peptides as the supply it wants people to leave.
The beginner map of the three product types is what are peptides?. The shopping questions, compounded drugs included, are on safety and buying. This page is the label itself.
Update, October 28, 2026
I checked the Federal Register public-inspection file and the policy PDF it points to, then NBC's story from the same day.
On October 28, 2026, HHS filed document 2026-22192. It publishes October 30. Comments stay open for two weeks after that publication date, docket HHS-OASH-2026-0496. The notice announces a draft enforcement-discretion policy for 503A compounding. Appendix A of the policy names BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The full conditions, including the prescription, the sourcing rules, the label line, and the route limits, are on is BPC-157 legal?.
The sentence that belongs on this page is the Secretary's reason. The policy says this limited discretion will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers, because those products pose a safety risk to US patients. Limited compounding, under the safeguards in the policy, is the alternative HHS describes. NBC News reported the same morning that a gray market sells these peptides with a research-use-only label, and that HHS has argued compounding would move people away from that market. Hilliard, an HHS spokesperson, told NBC the department is confronting black-market peptides.
Read that next to the August 24 letters. Those letters said a research-use-only line did not control when the rest of the website showed a human drug. The October 28 policy does not withdraw those letters. It does not say a research-use-only shop is now a pharmacy. The compounders it names are a state-licensed pharmacy, a federal facility, or a licensed physician, and only when the conditions are met. FDA has not approved the six peptides. The 503A Bulks List is unchanged. The notice calls the policy a draft and says it is not binding.
Health Canada's April 9, 2026 advisory is also unchanged. A research-use-only label still does not make an unauthorized injectable legal in Canada.
What the words are, and what they are not
A research-use-only line usually sits next to "not for human consumption" or "not for human or veterinary use." Those sentences are the seller's disclaimer. FDA's letters treat them as labeling the seller chose, then look at the rest of the website: disease claims, product names that match drugs, and accessories sold to prepare an injectable.
An approved medicine is a different object. Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo are named products with approval letters. The table is the GLP-1 drugs list. A vial that borrows one of those names and adds "research use only" is not that product.
A compounded copy is also a different object. Compounding has its own US statutes, shortage calendars, and warning letters about telehealth claims. Those files are compounded semaglutide vs Ozempic and compounded tirzepatide. A research-use-only website is not a 503A pharmacy and it is not a 503B outsourcing facility because it sells a powder.
A cosmetic cream is a third object. GHK-Cu creams are sold as cosmetics. The injection is not an approved drug. Status by route is is GHK-Cu FDA approved?.
What FDA said on August 24, 2026
FDA posted five warning letters that day, after reviewing the sites in July 2026:
- NuScience Peptides LLC, nusciencepeptides.com, letter 733652
- Peptide Partners LLC, peptide.partners, letter 735063
- Royal Peptides LLC, royal-peptides.com, letter 734884
- TXP Innovations LLC, doing business as Tex Peptides, texpeptide.com, letter 735067
- Peak Performance Peptides, pppepz.com, letter 735127
Read this next Safety and buying
Each letter says products named on the site, including products sold under semaglutide, tirzepatide, or retatrutide names, are unapproved new drugs. Introducing them into interstate commerce violates the FD&C Act, in FDA's account. The letters say injectable products are a particular concern because they are delivered into the body and bypass some defenses against toxins and microorganisms.
The footnote FDA repeats is the part that answers the label question. The sites said "research use only" and "not for human use," or a close variant. FDA said the websites still showed the products were intended as drugs for human use. The agency pointed to drug claims and to the sale of bacteriostatic water as a solvent, and in the Royal Peptides letter to a "peptide guide" and a "peptide calculator" sold alongside the vials. This page is not going to repeat any preparation steps from those letters. The point of the footnote is the legal theory: a disclaimer does not set the intended use when the rest of the page shows a human drug.
A warning letter is not a criminal conviction. FDA is telling those five firms, on that date, what the agency says the law requires. The letters do not cover every peptide website, and they say the lists of violations are not complete.
Canada
Health Canada's April 9, 2026 advisory names unauthorized injectable peptides it has seized, including BPC-157, and says the products are not authorized, have not been assessed for safety, efficacy, and quality, and that a research-use-only label does not make them legal. Authorized prescription drugs in Canada carry an eight-digit Drug Identification Number. A vial without one is not an authorized drug because the seller printed a laboratory sentence on it.
The single-peptide status file, including the US compounding record, is is BPC-157 legal?. The sport rule is a different document. The 2026 WADA list names BPC-157 in class S0. That file is is BPC-157 banned for athletes?.
What the studies do not answer
Most of the research so far comes from laboratory and animal studies. That does not tell us whether it works in people.
That sentence is the limit on compounds such as BPC-157, where the human pilots this site counts are fewer than 30 people and none of them is a published randomized trial. The list is BPC-157 human trials. It is the wrong sentence for semaglutide the approved drug, which has large human trials on the semaglutide profile. A research-use-only vial that uses the word semaglutide does not inherit those trials. The trials were of the approved products, in defined people, at labeled strengths.
We did not find reliable interaction data in the sources reviewed. That does not mean there are no interactions.
Common questions
What does research use only mean on a peptide vial?
It is a seller's label. FDA's August 24, 2026 letters say the phrase did not control intended use when the websites also showed human-drug claims and sold a solvent or a calculator for preparing the products. Health Canada's April 9, 2026 advisory says the phrase does not make an unauthorized injectable legal in Canada.
Does "not for human consumption" make the vial legal?
Not according to those letters and that advisory. The disclaimer is part of the labeling FDA and Health Canada looked past when the rest of the offer showed personal use.
Is a research-use-only vial the same as a compounded drug?
No. Compounded copies of approved drugs sit under the compounding rules and the shortage calendar. A research-chemical website is the subject of the August 24 letters. The October 28, 2026 HHS draft is about 503A compounding of six peptides under listed conditions. It names pharmacies, federal facilities, and physicians. It does not rename a research-use-only website as one of those.
Are research-use-only peptides FDA approved?
No. The letters call the named products unapproved new drugs. An approved product has an approval letter and a label. The GLP-1 drugs list is that file for the brand names.
Is BPC-157 covered by those August letters?
The August 24 letters name other products on those five sites. BPC-157 is one of the six peptides in Appendix A of the October 28, 2026 HHS draft. The US and Canadian record, including the conditions on that draft, is the legal-status page.
Sources
Methodology. Status checked October 26, 2026 against the five FDA warning letters dated August 24, 2026 and Health Canada's April 9, 2026 advisory. On October 28, 2026 we read Federal Register document 2026-22192, the HHS policy PDF, and the NBC News story from that day. The letters' preparation details are not repeated. The compounding conditions stay on the legal-status page. No seller inventory was compiled.
Primary sources.
- HHS, Federal Register public inspection, document 2026-22192, filed October 28, 2026: https://public-inspection.federalregister.gov/2026-22192.pdf
- HHS enforcement discretion policy PDF: https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- NBC News, Berkeley Lovelace Jr., October 28, 2026: https://www.nbcnews.com/health/health-news/rfk-jr-takes-shortcut-make-peptides-widely-available-rcna606133
- FDA warning letter, NuScience Peptides LLC, August 24, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
- FDA warning letter, Peptide Partners LLC, August 24, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
- FDA warning letter, Royal Peptides LLC, August 24, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026
- FDA warning letter, TXP Innovations LLC dba Tex Peptides, August 24, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026
- FDA warning letter, Peak Performance Peptides, August 24, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026
- Health Canada advisory, April 9, 2026: https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm
Changes. October 26, 2026: first published. October 28, 2026: added the HHS draft and the NBC report. The August 24 letters stay the record on the seller's label.
